AR059575A1 - Metodo para el tratamiento de enfermedades inflamatorias - Google Patents
Metodo para el tratamiento de enfermedades inflamatoriasInfo
- Publication number
- AR059575A1 AR059575A1 ARP070100595A ARP070100595A AR059575A1 AR 059575 A1 AR059575 A1 AR 059575A1 AR P070100595 A ARP070100595 A AR P070100595A AR P070100595 A ARP070100595 A AR P070100595A AR 059575 A1 AR059575 A1 AR 059575A1
- Authority
- AR
- Argentina
- Prior art keywords
- gaboxadol
- treatment
- inflammatory
- compound
- disease
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000027866 inflammatory disease Diseases 0.000 title abstract 2
- ZXRVKCBLGJOCEE-UHFFFAOYSA-N Gaboxadol Chemical compound C1NCCC2=C1ONC2=O ZXRVKCBLGJOCEE-UHFFFAOYSA-N 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229950004346 gaboxadol Drugs 0.000 abstract 4
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 abstract 2
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 2
- -1 cyclopropyl GABA Chemical compound 0.000 abstract 2
- ZJQHPWUVQPJPQT-UHFFFAOYSA-N muscimol Chemical compound NCC1=CC(=O)NO1 ZJQHPWUVQPJPQT-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229960002870 gabapentin Drugs 0.000 abstract 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
- PRJKNHOMHKJCEJ-UHFFFAOYSA-N imidazol-4-ylacetic acid Chemical compound OC(=O)CC1=CN=CN1 PRJKNHOMHKJCEJ-UHFFFAOYSA-N 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000005062 synaptic transmission Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Uso de gaboxadol, o una combinacion de gaboxadol y uno o más compuestos antiinflamatorios, para el tratamiento de una enfermedad inflamatoria. Composicion farmacéutica que comprende gaboxadol y uno o más compuestos antiinflamatorios. Un método para el tratamiento de una enfermedad en la cual uno o más marcadores inflamatorios están incrementados, que comprende administrar a un sujeto que lo necesita una cantidad terapéuticamente efectiva de un compuesto que potencia la neurotransmision GABAA- érgica. Reivindicacion 3: El método de acuerdo con la reivindicacion 1 o 2, en la cual el compuesto es seleccionado del grupo constituido por gaboxadol, ciclopropilGABA, isoguvacina, muscimol, ácido imidazol-4-acético, gabapentina y tiagabona, o una sal farmacéuticamente aceptable de los mismos.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77347506P | 2006-02-14 | 2006-02-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR059575A1 true AR059575A1 (es) | 2008-04-16 |
Family
ID=38162182
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP070100595A AR059575A1 (es) | 2006-02-14 | 2007-02-13 | Metodo para el tratamiento de enfermedades inflamatorias |
Country Status (15)
Country | Link |
---|---|
US (1) | US20070203216A1 (es) |
EP (1) | EP1986627A2 (es) |
JP (1) | JP2009526786A (es) |
KR (1) | KR20080098494A (es) |
CN (1) | CN101384254A (es) |
AR (1) | AR059575A1 (es) |
AU (1) | AU2007214860A1 (es) |
BR (1) | BRPI0707766A2 (es) |
CA (1) | CA2645734A1 (es) |
EA (1) | EA200870254A1 (es) |
IL (1) | IL193269A0 (es) |
MX (1) | MX2008010197A (es) |
NO (1) | NO20083885L (es) |
TW (1) | TW200836723A (es) |
WO (1) | WO2007093183A2 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2007006091A (es) * | 2007-05-21 | 2009-02-25 | World Trade Imp Export Wtie Ag | Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsionante. |
TW200920358A (en) * | 2007-08-13 | 2009-05-16 | Lundbeck & Co As H | Method of treating stress-mediated depression |
GB0810063D0 (en) * | 2008-06-03 | 2008-07-09 | Renovo Ltd | Medicaments and methods for inhibition of scarring |
JP2012506537A (ja) | 2008-10-21 | 2012-03-15 | アスチュート メディカル,インコーポレイテッド | 腎損傷および腎不全の診断および予後のための方法および組成物 |
US20110065136A1 (en) * | 2009-08-07 | 2011-03-17 | Rules-Based Medicine, Inc. | Methods and Devices for Detecting Glomerulonephritis and Associated Disorders |
JP5574331B2 (ja) * | 2010-06-04 | 2014-08-20 | 国立大学法人山口大学 | Nafldの進展度合いを判定する方法 |
NZ605698A (en) | 2010-06-23 | 2015-03-27 | Astute Medical Inc | Methods and compositions for diagnosis and prognosis of renal injury and renal failure |
KR101353570B1 (ko) * | 2010-09-16 | 2014-01-22 | 경북대학교 산학협력단 | 클러스터린 발현 또는 활성 촉진제를 포함하는 지방간 예방 및 치료용 조성물 |
EP2621282B1 (en) * | 2010-09-28 | 2020-04-15 | The Regents of The University of California | Gaba agonists in the treatment of disorders associated with metabolic syndrome and gaba combinations in treatment or prophylaxis of type i diabetes |
CN102749448B (zh) * | 2012-07-27 | 2014-07-02 | 复旦大学附属中山医院 | 用于评估肺腺癌化疗效果的试剂盒 |
US9381171B2 (en) | 2013-12-19 | 2016-07-05 | Samsung Electronics Co., Ltd. | Composition including dapsone for preventing or treating side effect of steroid in subject and use of the composition |
WO2016090002A1 (en) * | 2014-12-04 | 2016-06-09 | Board Of Regents Of The University Of Texas System | Recombinant clusterin and use thereof in the treatment and prevention of disease |
EP3349854A4 (en) | 2015-09-17 | 2019-04-03 | Amgen Inc. | PREDICTING THE CLINICAL RESPONSE TO IL23 ANTAGONISTS WITH IL23 PATIENT BIOMARKERS |
EP3577458A4 (en) | 2017-02-06 | 2021-04-07 | Astute Medical, Inc. | METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PREDICTION OF RENAL LESION AND RENAL INSUFFICIENCY |
WO2018159787A1 (ja) * | 2017-03-01 | 2018-09-07 | 国立大学法人北海道大学 | 疾患モデル非ヒト動物の製造方法、疾患モデル非ヒト動物、該動物を用いた薬剤のスクリーニング方法及び疾患リスク判定方法 |
WO2018236955A1 (en) * | 2017-06-23 | 2018-12-27 | The Regents Of The University Of California | IMPROVING GABA CAPACITY TO MODULATE IMMUNE RESPONSES |
GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
WO2019075136A1 (en) * | 2017-10-10 | 2019-04-18 | Aldeyra Therapeutics, Inc. | TREATMENT OF INFLAMMATORY DISORDERS |
CN112888437A (zh) * | 2018-08-22 | 2021-06-01 | 奥维德医疗公司 | 加波沙朵在治疗胃肠道紊乱和哮喘中的用途 |
WO2020212948A1 (en) | 2019-04-17 | 2020-10-22 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
US20240269206A1 (en) * | 2021-08-11 | 2024-08-15 | Psyched Wellness Ltd. | Amanita muscaria extracts and compounds and their beneficial and therapeutic use |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK270378A (da) * | 1977-06-20 | 1978-12-21 | Krogsgaard Larsen P | Isoxazolderivater |
US5767117A (en) * | 1994-11-18 | 1998-06-16 | The General Hospital Corporation | Method for treating vascular headaches |
US6329429B1 (en) * | 1997-06-25 | 2001-12-11 | Warner-Lambert Company | Use of GABA analogs such as Gabapentin in the manufacture of a medicament for treating inflammatory diseases |
DE69927960T2 (de) * | 1998-03-11 | 2006-07-20 | Torbjörn Backström | Epiallopregnanolon zur behandlung von krankheiten des cns |
US6350769B1 (en) * | 1999-02-24 | 2002-02-26 | The Regents Of The University Of California | Gaba alpha receptors mediate inhibition of T cell responses |
CN1976700A (zh) * | 2004-06-29 | 2007-06-06 | H.隆德贝克有限公司 | 神经性疼痛、纤维肌痛或类风湿关节炎的治疗 |
-
2007
- 2007-02-12 US US11/673,898 patent/US20070203216A1/en not_active Abandoned
- 2007-02-13 AR ARP070100595A patent/AR059575A1/es unknown
- 2007-02-13 KR KR1020087020060A patent/KR20080098494A/ko not_active Application Discontinuation
- 2007-02-13 CA CA002645734A patent/CA2645734A1/en not_active Abandoned
- 2007-02-13 EA EA200870254A patent/EA200870254A1/ru unknown
- 2007-02-13 MX MX2008010197A patent/MX2008010197A/es not_active Application Discontinuation
- 2007-02-13 WO PCT/DK2007/050019 patent/WO2007093183A2/en active Application Filing
- 2007-02-13 BR BRPI0707766-1A patent/BRPI0707766A2/pt not_active IP Right Cessation
- 2007-02-13 AU AU2007214860A patent/AU2007214860A1/en not_active Abandoned
- 2007-02-13 EP EP07711307A patent/EP1986627A2/en not_active Withdrawn
- 2007-02-13 CN CNA2007800052625A patent/CN101384254A/zh active Pending
- 2007-02-13 JP JP2008554598A patent/JP2009526786A/ja not_active Withdrawn
- 2007-03-01 TW TW096106933A patent/TW200836723A/zh unknown
-
2008
- 2008-08-05 IL IL193269A patent/IL193269A0/en unknown
- 2008-09-12 NO NO20083885A patent/NO20083885L/no unknown
Also Published As
Publication number | Publication date |
---|---|
CA2645734A1 (en) | 2007-08-23 |
EA200870254A1 (ru) | 2008-12-30 |
NO20083885L (no) | 2008-09-12 |
WO2007093183A3 (en) | 2007-11-22 |
IL193269A0 (en) | 2009-08-03 |
US20070203216A1 (en) | 2007-08-30 |
BRPI0707766A2 (pt) | 2011-05-10 |
TW200836723A (en) | 2008-09-16 |
EP1986627A2 (en) | 2008-11-05 |
KR20080098494A (ko) | 2008-11-10 |
WO2007093183A2 (en) | 2007-08-23 |
MX2008010197A (es) | 2008-09-26 |
JP2009526786A (ja) | 2009-07-23 |
AU2007214860A1 (en) | 2007-08-23 |
CN101384254A (zh) | 2009-03-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR059575A1 (es) | Metodo para el tratamiento de enfermedades inflamatorias | |
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
ECSP17013617A (es) | combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid | |
AR072442A1 (es) | Metodo para la terapia del cancer, uso, kit | |
RU2013121788A (ru) | Ингибиторы репликации вич | |
AR067903A1 (es) | Metodo para tratar la depresion mediada por estres | |
AR053809A1 (es) | Combinacion de compuestos organicos | |
UY33479A (es) | Compuestos terapeuticos, composicion farmaceutica que lo comprende, metodo de tratamiento y su uso para la manufactura de un medicamento | |
AR091876A1 (es) | Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas | |
UY35624A (es) | Uso de dosis elevadas de pridopidina para tratar la enfermedad de huntington | |
CR20120062A (es) | Terapia combinada para el tratamiento de la diabetes | |
AR085662A1 (es) | Metodos y composiciones para tratar la hiperuricemia y trastornos metabolicos asociados con la hiperuricemia | |
CR9721A (es) | Compuestos de carbamato para utilizar en el tratamiento de desordenes neurodegenerativos | |
RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
UY33221A (es) | MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA | |
AR084216A1 (es) | Composiciones y metodos para tratar el cancer usando un inhibidor de pi3k e inhibidor de mek, kit | |
EA200970127A1 (ru) | Модулятор рецепторов глюкокортикостероидов и способы его применения | |
AR101901A1 (es) | Tratamiento de enfermedades neurodegenerativas con una combinación de laquinimod y fingolimod | |
ES2582660T3 (es) | Sidnoniminas - inhibidores específicos de la recaptación de la dopamina y su uso en el tratamiento de los trastornos relacionados con la dopamina | |
ECSP088545A (es) | Composición para prevenir o tratar daños de la mucosa en los conductos gastrointestinales | |
UY31826A (es) | Compuesto peptídico y su uso | |
CL2007000485A1 (es) | Sal de alisquereno; procedimiento de preparacion; composicion farmaceutica que comprende a dicha sal; y uso del compuesto para el tratamiento de enfermedades que puedan ser moduladas mediante la inhibicion de la renina. | |
AR111697A2 (es) | Composición oftálmica para el tratamiento de las alergias oculares | |
CL2008001477A1 (es) | Composicion farmaceutica compuesta por la combinacion sinergica de un agente anticonvulsivante como gabapentina y un agente antiinflamatorio no esteroideo como meloxicam, los rangos de concentracion presentes para la gabapentina son 3 a 300 mg y de 0,1 a 30 mg para meloxicam; y uso para tratar el dolor neuropatico | |
AR088735A1 (es) | Compuestos de tienopirimidina que son inhibidores de canal de potasio |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |